Minerva Neurosciences | NERV - Operating Expenses


Minerva Neurosciences reported $4.52M in Operating Expenses for its fiscal quarter ending in December of 2024.





Operating Expenses Change Date
Acadia Pharmaceuticals USD 266.6M 23.72M Dec/2025
Adma Biologics USD 83.21M 4.02M Sep/2025
ALKERMES USD 326.44M 1.41B Dec/2025
Alterity Therapeutics Limited AUD 7.78M 3M Jun/2023
AstraZeneca USD 12.53B 4.16B Dec/2025
BioCryst Pharmaceuticals USD -387.89M 33.7M Sep/2025
Bristol-Myers Squibb USD 8.3B 10.25B Dec/2025
Cipla INR 60.98B 1.06B Dec/2025
Clal Biotechnology ILS 5.15M 9.47M Dec/2022
Compugen USD 9.78M 90K Sep/2025
CSL USD 5.7B 2.82B Dec/2025
Eli Lilly USD 10.31B 1.09B Dec/2025
Esperion Therapeutics USD 67.66M 3.6M Sep/2024
GlaxoSmithKline GBP 7.18B 1.42B Dec/2025
Grifols EUR 1.77B 22.04M Sep/2025
Halozyme Therapeutics USD 211.07M 74.73M Dec/2025
Ionis Pharmaceuticals USD 418M 101.1M Dec/2025
J&J USD 18.97B 2.38B Dec/2025
Merck USD 10.16B 558M Dec/2025
Minerva Neurosciences USD 4.52M 155.46K Dec/2024
Neurocrine Biosciences USD 577.6M 22M Dec/2025
Novartis USD 9.86B 115M Sep/2025
Novavax USD 218.53M 34.86M Sep/2024
Pfizer USD 12.91B 79.89B Dec/2025
Roche Holding CHF 21.01B 10.84B Dec/2025
Sanofi EUR 10.51B 1.21B Dec/2025
Takeda JPY 1.02T 400.98B Dec/2025
Vanda Pharmaceuticals USD 466M 20.33M Sep/2025